BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32295135)

  • 1. Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer.
    Bommireddy R; Munoz LE; Kumari A; Huang L; Fan Y; Monterroza L; Pack CD; Ramachandiran S; Reddy SJC; Kim J; Chen ZG; Saba NF; Shin DM; Selvaraj P
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32295135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.
    Pack CD; Bommireddy R; Munoz LE; Patel JM; Bozeman EN; Dey P; Radhakrishnan V; Vartabedian VF; Venkat K; Ramachandiran S; Reddy SJC; Selvaraj P
    Hum Vaccin Immunother; 2020 Dec; 16(12):3184-3193. PubMed ID: 32530786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
    Zhou L; Zeng Z; Egloff AM; Zhang F; Guo F; Campbell KM; Du P; Fu J; Zolkind P; Ma X; Zhang Z; Zhang Y; Wang X; Gu S; Riley R; Nakahori Y; Keegan J; Haddad R; Schoenfeld JD; Griffith O; Manguso RT; Lederer JA; Liu XS; Uppaluri R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers.
    Rykkelid AM; Sinha PM; Folefac CA; Horsman MR; Sørensen BS; Søland TM; Schreurs OJF; Malinen E; Edin NFJ
    Sci Rep; 2024 May; 14(1):11569. PubMed ID: 38773258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis.
    Yang LL; Wu L; Yu GT; Zhang WF; Liu B; Sun ZJ
    J Dent Res; 2018 Jul; 97(7):787-794. PubMed ID: 29486141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
    Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
    Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
    Front Immunol; 2019; 10():1206. PubMed ID: 31214178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
    Anderson K; Ryan N; Alkhimovitch A; Siddiqui A; Oghumu S
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
    Kao HF; Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Head and neck cancer : promising results of immunotherapy].
    Sivade A; Bensaid D; Monnier Y; Shabafrouz K; Bouchaab H; Cristina V
    Rev Med Suisse; 2017 May; 13(563):1029-1031. PubMed ID: 28636292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
    Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
    Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
    Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
    Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
    Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
    J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.